Font Size: 

Background: Pentagamavunon-1 (PGV-1), a curcumin analog, has been reported to have strong anti-proliferative activities against several breast cancer cells. Objective: The aim of this research is to observe the effect of PGV-1 on triple negative breast cancer cell line, which was known as a highly metastatic cancer cells. Since breast cancer frequently metastasizes to the bone, we also investigated the effect of PGV-1 on osteoclast differentiation. Materials and Methods: ODF-induced RAW 264.7 cells and Bone Marrow Macrophage (BMM) cells were used as the in vitro osteoclastogenenesis model. Cytotoxicity assay were conducted using MTT assay while cell migration on MDA-MB-231 was examined by using scratch wound healing assay and lamellipodia formation. The effect of the PGV-1 on the osteoclast differentiation was observed by TRAP staining. Results: The PGV-1 IC₅₀ on MDA-MB-231 and RAW 264.7 cells were 20 μM and 3 μM, respectively. PGV-1 inhibited cell migration in a dose dependent manner where at the highest treatment concentration (1/4 IC₅₀), it decreased the percent closure up to 70%. Observation on lamellipodia formation showed that 5 μM PGV-1 inhibited the formation up to 25%. Although PGV-1 showed a cytotoxic effect on RAW 264.7 cells it had no effect on BMM cells. PGV-1 at a low concentration had no effect on the osteoclast formation in any step of osteoclastogenesis. Furthermore, at a higher concentration, PGV-1 decreased osteoclast number on ODF-induced RAW 264.7 but not on the BMM osteoclast differentiation. The decreasing osteoclast occurring was correlated to the cytotoxic effect of PGV-1. Conclusion: PGV-1 performed antimigratory effect on TNBC cells and did not affect the osteoclastogenesis on BMM cells. Therefore, PGV-1 is considered to be a good candidate for anti-migration agent but safe for the bone remodeling.